Stay informed, stay ahead.
hinese biotech company Innovent Biologics has signed a massive deal with Japan’s Takeda Pharmaceutical. The agreement is valued up to $1.14 billion. This partnership focuses on developing and commercializing a promising new cancer therapy. This collaboration highlights the growing importance of China’s biomedical sector. Innovent will lead the development and regulatory filings in mainland China….
Merck has begun work on a $3 billion manufacturing facility in Elkton, Virginia, as part of its plan to ramp up U.S. production. The new plant will span about 400,000 square feet and focus on small-molecule drug manufacturing and testing. Merck said the investment will create over 500 full-time jobs and roughly 8,000 construction roles…
Researchers have found early signs that an mRNA vaccine — like those used for COVID-19 — could help the immune system fight certain cancers. In a study involving more than 1,000 patients with advanced lung or skin cancer, people who received an mRNA vaccine within 100 days of starting immunotherapy lived significantly longer. This suggests…
Molecular diagnostics company BillionToOne is preparing to go public in the U.S., aiming for a valuation of up to $2.42 billion. Based in Menlo Park, California, the firm plans to offer up to 3.8 million shares at a price range of $49 to $55 each, raising as much as $211.5 million. BillionToOne develops advanced disease-diagnostic…
At CNBC’s “Invest in America” forum, Wells Fargo CEO Charlie Scharf and Pfizer CEO Albert Bourla warned that the U.S. risks falling behind China if it doesn’t double down on innovation. Scharf said that while AI tools are boosting productivity — with coders seeing 20–40% performance gains — the nation must guard against policy uncertainty…
